Measurements of Tumor Cell Autophagy Predict Invasiveness, Resistance to Chemotherapy, and Survival in Melanoma

Purpose: Autophagy consists of lysosome-dependent degradation of cytoplasmic contents sequestered by autophagic vesicles (AV). The role of autophagy in determining tumor aggressiveness and response to therapy in melanoma was investigated in this study. Experimental Design: Autophagy was measured in tumor biopsies obtained from metastatic melanoma patients enrolled on a phase II trial of temozolomide and sorafenib and correlated to clinical outcome. These results were compared with autophagy measurements in aggressive and indolent melanoma cells grown in two- and three-dimensional (3D) culture and as xenograft tumors. The effects of autophagy inhibition with either hydroxychloroquine or inducible shRNA (short hairpin RNA) against the autophagy gene ATG5 were assessed in three-dimensional spheroids. Results: Patients whose tumors had a high autophagic index were less likely to respond to treatment and had a shorter survival compared with those with a low autophagic index. Differences in autophagy were less evident in aggressive and indolent melanoma cells grown in monolayer culture. In contrast, autophagy was increased in aggressive compared with indolent melanoma xenograft tumors. This difference was recapitulated when aggressive and indolent melanoma cells were grown as spheroids. Autophagy inhibition with either hydroxychloroquine or inducible shRNA against ATG5 resulted in cell death in aggressive melanoma spheroids, and significantly augmented temozolomide-induced cell death. Conclusions: Autophagy is a potential prognostic factor and therapeutic target in melanoma. Three dimensional culture mimics the tumor microenvironment better than monolayer culture and is an appropriate model for studying therapeutic combinations involving autophagy modulators. Autophagy inhibition should be tested clinically in patients with melanoma. Clin Cancer Res; 17(10); 3478–89. ©2011 AACR.

[1]  Keith T Flaherty,et al.  Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases , 2006, Molecular Cancer Therapeutics.

[2]  Donna Niedzwiecki,et al.  Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. Dyer,et al.  Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. , 2009, The Journal of clinical investigation.

[4]  Gyan Bhanot,et al.  Autophagy Suppresses Tumorigenesis through Elimination of p62 , 2009, Cell.

[5]  KyungMann Kim,et al.  Induction of autophagy and inhibition of melanoma growth in vitro and in vivo by hyperactivation of oncogenic BRAF. , 2010, The Journal of investigative dermatology.

[6]  Michael G. Roth,et al.  Genome-Wide siRNA-Based Functional Genomics of Pigmentation Identifies Novel Genes and Pathways That Impact Melanogenesis in Human Cells , 2008, PLoS genetics.

[7]  Jie Xu,et al.  Elevated Beclin 1 expression is correlated with HIF-1α in predicting poor prognosis of nasopharyngeal carcinoma , 2010, Autophagy.

[8]  Kevin Bray,et al.  Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. , 2006, Cancer cell.

[9]  E. Morselli,et al.  Control of autophagy by oncogenes and tumor suppressor genes , 2009, Cell Death and Differentiation.

[10]  E. White,et al.  Autophagy suppresses tumor progression by limiting chromosomal instability. , 2007, Genes & development.

[11]  M. Hendrix,et al.  Selection of invasive and metastatic subpopulations from a heterogeneous human melanoma cell line. , 1990, BioTechniques.

[12]  K. Flaherty,et al.  Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases , 2009, Clinical Cancer Research.

[13]  Britton Chance,et al.  Quantitative magnetic resonance and optical imaging biomarkers of melanoma metastatic potential , 2009, Proceedings of the National Academy of Sciences.

[14]  Russell G. Jones,et al.  Tumor suppressors and cell metabolism: a recipe for cancer growth. , 2009, Genes & development.

[15]  J. Cleveland,et al.  Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. , 2007, Blood.

[16]  M. Berger,et al.  DNA damaging agent-induced autophagy produces a cytoprotective adenosine triphosphate surge in malignant glioma cells , 2007, Cell Death and Differentiation.

[17]  A. Harris,et al.  Regulation of autophagy by ATF4 in response to severe hypoxia , 2010, Oncogene.

[18]  K. Flaherty,et al.  Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression. , 2008, Cancer research.

[19]  Zhen Lu,et al.  The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. , 2008, The Journal of clinical investigation.

[20]  Ashutosh Kumar Singh,et al.  A Non-canonical MEK/ERK Signaling Pathway Regulates Autophagy via Regulating Beclin 1* , 2009, The Journal of Biological Chemistry.

[21]  E. Seftor,et al.  Characterization of a highly invasive and spontaneously metastatic human malignant melanoma cell line , 1991, International journal of cancer.

[22]  Shoko Nioka,et al.  Histological basis of MR/optical imaging of human melanoma mouse xenografts spanning a range of metastatic potentials. , 2009, Advances in experimental medicine and biology.

[23]  R A Knight,et al.  Classification of cell death: recommendations of the Nomenclature Committee on Cell Death , 2005, Cell Death and Differentiation.

[24]  John L Cleveland,et al.  Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis. , 2008, The Journal of clinical investigation.

[25]  Govind Bhagat,et al.  Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. , 2003, The Journal of clinical investigation.

[26]  C. Bucana,et al.  Direct correlation between MUC18 expression and metastatic potential of human melanoma cells. , 1993, Melanoma research.

[27]  Damien Kee,et al.  Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. , 2010, Cancer cell.

[28]  C. Thompson,et al.  The Roles of Therapy-Induced Autophagy and Necrosis in Cancer Treatment , 2007, Clinical Cancer Research.

[29]  J. Barata,et al.  PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. , 2008, The Journal of clinical investigation.

[30]  I. Germano,et al.  Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells , 2004, Cell Death and Differentiation.

[31]  Britton Chance,et al.  Predicting melanoma metastatic potential by optical and magnetic resonance imaging. , 2007, Advances in experimental medicine and biology.

[32]  D. Stolz,et al.  Oncogenic transformation confers a selective susceptibility to the combined suppression of the proteasome and autophagy , 2009, Molecular Cancer Therapeutics.

[33]  Chi Li,et al.  Growth Factor Regulation of Autophagy and Cell Survival in the Absence of Apoptosis , 2005, Cell.

[34]  K. Flaherty,et al.  Targeted therapy for metastatic melanoma. , 2007, Clinical advances in hematology & oncology : H&O.

[35]  K. Flaherty,et al.  The MAPK pathway in melanoma , 2008, Current opinion in oncology.

[36]  Daniel J. Klionsky,et al.  Autophagy fights disease through cellular self-digestion , 2008, Nature.

[37]  T. Ueno,et al.  LC3 conjugation system in mammalian autophagy , 2004, The International Journal of Biochemistry & Cell Biology.

[38]  R A Knight,et al.  Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009 , 2005, Cell Death and Differentiation.

[39]  M. Hendrix,et al.  A simple quantitative assay for studying the invasive potential of high and low human metastatic variants. , 1987, Cancer letters.

[40]  E. White,et al.  The Double-Edged Sword of Autophagy Modulation in Cancer , 2009, Clinical Cancer Research.

[41]  G. Evan,et al.  Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. , 2007, The Journal of clinical investigation.